Literature DB >> 28119378

Guanidinoacetate methyltransferase (GAMT) deficiency: a rare but treatable epilepsy.

William M Stern1,2, Joel S Winston3,4, Elaine Murphy5, J Helen Cross6, Josemir W Sander1,2,7.   

Abstract

Epilepsy commonly presents in childhood as part of a syndrome, and some such children may reach adult services without an underlying syndromic diagnosis. For adult neurologists taking over their care, it is often unclear how hard to search for an underlying diagnosis. The diagnostic yield may be small and such a diagnosis may not change management. Young adults with learning difficulties are also challenging to investigate, as they may not tolerate standard epilepsy tests.We present such a case in which simple tests identified a unifying diagnosis. With the new diagnosis came a new treatment that had a significant impact on seizures and quality of life. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28119378     DOI: 10.1136/practneurol-2016-001475

Source DB:  PubMed          Journal:  Pract Neurol        ISSN: 1474-7758


  3 in total

Review 1.  Intellectual Disability and Brain Creatine Deficit: Phenotyping of the Genetic Mouse Model for GAMT Deficiency.

Authors:  Luigia Rossi; Francesca Nardecchia; Francesca Pierigè; Rossella Ventura; Claudia Carducci; Vincenzo Leuzzi; Mauro Magnani; Simona Cabib; Tiziana Pascucci
Journal:  Genes (Basel)       Date:  2021-08-02       Impact factor: 4.096

Review 2.  Rare and Complex Epilepsies from Childhood to Adulthood: Requirements for Separate Management or Scope for a Lifespan Holistic Approach?

Authors:  Simona Balestrini; Renzo Guerrini; Sanjay M Sisodiya
Journal:  Curr Neurol Neurosci Rep       Date:  2021-11-24       Impact factor: 5.081

Review 3.  Precision medicine and therapies of the future.

Authors:  Sanjay M Sisodiya
Journal:  Epilepsia       Date:  2020-07-24       Impact factor: 6.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.